Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Cuddo.
"42% above 2.1p here is 3p"
The problem is that ,I would suggest , 99% of nfx share holders are way above 3p.
My personal average is 4.2, which is convenient as I need 100% from 2.1.
ATB
O/T
Started to get nervous with my he1 so took my profit (42%) . Once bitten twice shy.
Apologies for that o/t
Roll on some positive up front news from Anne.
ATB
I agree SSM, I shouldn't still hold nfx, and over the past wee while have sold most and now hold just 200,000. I moved some into ANG at 60p. and the last tranche I sold at a 56% loss, I moved into he1 at 18p. ( though this could go either way very quickly).
If we get the Oxilio deal over the line and get a decently positive blip in the sp it'll probably be time to sell the rest. And I say if we get the Oxilio deal as I believe they are having a problem raising the required funds.
ATB
The past is the past. No point dwelling on what has been.
We know that NXP002 outperforms Esbriet on a standalone basis and improves care in combination with that and Ofev, now we just await results of the inhaler feasibility.
And just need Ox to come up with some cash and sign on the dotted line.
Reasons to be cheerful....part 3.....
Fair point chab but if I shared your belief I would no longer be invested in nfx, I would also not still be bothering to follow the company as what value is left if you cant trust any of the previous work conducted?
SSm. "The points/concerns you raise on the article leak, subsequent late reporting, the undisclosed payments etc. I also share but are unrelated to the original comment you made"
I disagree. I think they are totally related. The point being is whether during the period up until Anne joined can we believe anything that was stayed by previous board members, and in my opinion we can't. One finds in life that history repeats itself, and nfx's history has been one kick in the balls after another.
So no Gov grant. Shame. Wonder why.
So roll on news about Oxilio eh?
ATB
Not having a go but your twisting my words chab, I'm clearly not saying that you cant invest in or comment on nfx I'm saying I dont think you can safely say that what chris said in his interview last year was BS. Pre clinical studies are underway to generate a more robust data package, this data will come in time. It is also a potential reason as to why we lost out on the innovate grant, just a thought. I would also note that CB indicated treatments for covid19 not long covid and he clearly referenced it needed clinical validation. I'm also significantly in the red in nfx but wont claim that they have given us BS on any of the tech just yet, I would have sold if i thought that and i assume u still hold some faith too as you're still here. It should also be noted that they're still investigating the causes of long covid even now, so chances are nxp002 may not target the relevant area we simply dont know yet. Not knowing something, hypothesizing and then testing to validate and draw your conclusion is science not BS. Even if it turns out CB was wrong on nxp002 links to a potential covid treatment it's a reasonable hypothesis to make given what nxp002 does and that severe cases of covid19 can cause inflammation and scaring of the lungs. We just have to wait and see. The points/concerns you raise on the article leak, subsequent late reporting, the undisclosed payments etc. I also share but are unrelated to the original comment you made
Agree with Chab, and no-one can argue against thinking like that, the evidence is all there.
Have faith that Anne knows what she's doing and we'll see things improve fingers crossed
My bad, (odd expression). I had no idea that only those working in the biotech sector were allowed to invest in Nfx.
As an investor I would I have thought my opinion of how this company worked up until Anne came on board was as allowed.
Seen more BS from this company over the years than most . Whether it be leaked false information to the press to enable certain board members to profit on the back of pi's. Or the Ebers millions. Or those most trumpeted "substation undisclosed" payments. Then six to nine months into the pandemic the bod trying to play catch.
So you'll have to excuse me if with this company it's "I'll believe it when I see it".
ATB
Now why would they get turned down for a grant that would assist research into a potential treatment for something as damaging as Covid or long Covid?
It doesn't make sense if there is any chance that it could be effective.
"After the period end, the Group submitted an application for an Innovate UK Grant to support the development of
NXP002 in IPF and with potential in other respiratory diseases including respiratory complications arising as a
result of Covid-19."
Unfortunately the company didn't get the Innovate Grant.
"An ambition of the Board is development of some of the Group assets for the treatment of Covid19. The Board has previously confirmed, in conjunction with its network of key opinion leaders, that it had started to review and assess emerging academic data that suggests coronaviruses can trigger hyperinflammation through activation of the biological target known as the NLRP3 inflammasome, making NXP002 a potential novel drug target to treat Covid-19.
This, together with potential future licensing opportunities for NXP002 in both IPF and Covid-19, makes it important to explore all licensing possibilities to maximise value for shareholders. Business development opportunities will therefore be expanded, to exploit the potential for licensing NXP002 for global markets, to continue to pursue licensing opportunities identified for the Asian market, and to explore potential development interest in the treatment of Covid-19."
Dont be so quick to discredit Chris Blackwell's remarks about this last year. Fact of the matter is nxp002 needs further validation/ data which is underway. Long covid isn't going anywhere anytime soon unfortunately. Please do enlighten us all on why you think CBs comments were BS? Do you work in the biotech sector?
We all know why that was thrown out there. Looked like BS at the time and subsequently turned out to be BS.
They'd have prioritised it if there was any whiff of it having an impact.
Feels like we missed the boat on that one, unless we get a nice suprise for a change
..now reported in the UK from various press and TV media today.
https://mol.im/a/9717715
Shame nothing materialised from Blackwell's early rumblings on the possibility of NXP002 being a potential treatment for the lung inflammation symptoms.